Allianz Asset Management GmbH Sells 15,437 Shares of MEDNAX Inc (MD)
Allianz Asset Management GmbH lowered its position in shares of MEDNAX Inc (NYSE:MD) by 30.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 34,753 shares of the company’s stock after selling 15,437 shares during the period. Allianz Asset Management GmbH’s holdings in MEDNAX were worth $1,498,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in MD. Schwab Charles Investment Management Inc. grew its position in shares of MEDNAX by 5.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 295,514 shares of the company’s stock worth $17,841,000 after acquiring an additional 15,715 shares during the last quarter. Bank of New York Mellon Corp grew its position in MEDNAX by 7.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,304,975 shares of the company’s stock valued at $78,782,000 after buying an additional 90,002 shares in the last quarter. Legal & General Group Plc grew its position in MEDNAX by 14.6% in the 2nd quarter. Legal & General Group Plc now owns 156,414 shares of the company’s stock valued at $9,443,000 after buying an additional 19,869 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in MEDNAX by 115.8% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 52,850 shares of the company’s stock valued at $3,191,000 after buying an additional 28,359 shares in the last quarter. Finally, Marshall Wace North America L.P. bought a new position in MEDNAX in the 2nd quarter valued at about $5,912,000. Institutional investors and hedge funds own 98.43% of the company’s stock.
Shares of MEDNAX Inc (MD) opened at $53.05 on Wednesday. MEDNAX Inc has a 1-year low of $40.56 and a 1-year high of $72.13. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.37 and a quick ratio of 1.37. The firm has a market cap of $5,012.43, a PE ratio of 18.75, a price-to-earnings-growth ratio of 1.72 and a beta of 0.40.
MEDNAX (NYSE:MD) last issued its quarterly earnings results on Wednesday, November 1st. The company reported $0.87 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.87. MEDNAX had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million during the quarter, compared to the consensus estimate of $864.78 million. During the same period in the prior year, the company earned $1.09 EPS. MEDNAX’s revenue was up 4.9% on a year-over-year basis. equities research analysts anticipate that MEDNAX Inc will post 3.1 earnings per share for the current fiscal year.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the company’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the sale, the insider now directly owns 35,569 shares of the company’s stock, valued at approximately $1,834,649.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Cesar L. Alvarez sold 10,668 shares of the company’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the completion of the sale, the director now directly owns 44,215 shares of the company’s stock, valued at $1,883,116.85. The disclosure for this sale can be found here. 2.40% of the stock is currently owned by corporate insiders.
A number of equities analysts recently issued reports on the stock. Jefferies Group reiterated a “hold” rating and issued a $44.00 target price on shares of MEDNAX in a research report on Friday, November 3rd. KeyCorp upgraded shares of MEDNAX from a “sector weight” rating to an “overweight” rating and set a $51.00 target price for the company in a research report on Sunday, September 17th. Citigroup decreased their target price on shares of MEDNAX from $52.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. BMO Capital Markets assumed coverage on shares of MEDNAX in a research report on Monday, October 16th. They issued a “market perform” rating and a $46.00 target price for the company. Finally, Robert W. Baird increased their target price on shares of MEDNAX from $47.00 to $48.00 and gave the company a “neutral” rating in a research report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $53.82.
TRADEMARK VIOLATION WARNING: This news story was posted by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/allianz-asset-management-gmbh-sells-15437-shares-of-mednax-inc-md/1784625.html.
MEDNAX Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with Analyst Ratings Network's FREE daily email newsletter.